A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer

Patricia L. Judson, C. Blair Harkness, Matthew P. Boente, Levi S. Downs, Peter A. Argenta, Linda F. Carson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives. To assess the antitumor activity of Temozolomide, a novel alkylating agent, in patients with persistent or recurrent ovarian or primary peritoneal carcinoma who have failed other second-line chemotherapy agents. To identify the nature and degree of toxicity of Temozolomide in this group of patients. Methods. Temozolomide was administered orally at an initial dose of 150 mg/m2 daily for 5 days, every 4 weeks. If the initial course was tolerated without dose-limiting toxicity, then the dose was increased to 200 mg/m2. Patients were evaluated for response and toxicity. Results. Fifteen patients were enrolled and evaluated. The median number of prior treatment regimens was 3. Hematologic toxicity was encountered in 26% of patients and was manageable. There were no complete or partial responses. One patient had stable disease with significant improvement in her performance status while on treatment. Conclusion. This dose and schedule of Temozolomide had insignificant activity in this heavily pretreated group of patients with persistent or recurrent ovarian or primary peritoneal carcinoma.

Original languageEnglish (US)
Pages (from-to)667-670
Number of pages4
JournalGynecologic oncology
Volume93
Issue number3
DOIs
StatePublished - Jun 1 2004

Fingerprint

temozolomide
Carcinoma
Alkylating Agents
Ovarian epithelial cancer
Appointments and Schedules

Keywords

  • Peritoneal carcinoma
  • Temozolomide
  • Toxicity

Cite this

A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer. / Judson, Patricia L.; Harkness, C. Blair; Boente, Matthew P.; Downs, Levi S.; Argenta, Peter A.; Carson, Linda F.

In: Gynecologic oncology, Vol. 93, No. 3, 01.06.2004, p. 667-670.

Research output: Contribution to journalArticle

Judson, Patricia L. ; Harkness, C. Blair ; Boente, Matthew P. ; Downs, Levi S. ; Argenta, Peter A. ; Carson, Linda F. / A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer. In: Gynecologic oncology. 2004 ; Vol. 93, No. 3. pp. 667-670.
@article{5c01154d6fe5416b8f246b01fde0eed7,
title = "A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer",
abstract = "Objectives. To assess the antitumor activity of Temozolomide, a novel alkylating agent, in patients with persistent or recurrent ovarian or primary peritoneal carcinoma who have failed other second-line chemotherapy agents. To identify the nature and degree of toxicity of Temozolomide in this group of patients. Methods. Temozolomide was administered orally at an initial dose of 150 mg/m2 daily for 5 days, every 4 weeks. If the initial course was tolerated without dose-limiting toxicity, then the dose was increased to 200 mg/m2. Patients were evaluated for response and toxicity. Results. Fifteen patients were enrolled and evaluated. The median number of prior treatment regimens was 3. Hematologic toxicity was encountered in 26{\%} of patients and was manageable. There were no complete or partial responses. One patient had stable disease with significant improvement in her performance status while on treatment. Conclusion. This dose and schedule of Temozolomide had insignificant activity in this heavily pretreated group of patients with persistent or recurrent ovarian or primary peritoneal carcinoma.",
keywords = "Peritoneal carcinoma, Temozolomide, Toxicity",
author = "Judson, {Patricia L.} and Harkness, {C. Blair} and Boente, {Matthew P.} and Downs, {Levi S.} and Argenta, {Peter A.} and Carson, {Linda F.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1016/j.ygyno.2004.03.020",
language = "English (US)",
volume = "93",
pages = "667--670",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer

AU - Judson, Patricia L.

AU - Harkness, C. Blair

AU - Boente, Matthew P.

AU - Downs, Levi S.

AU - Argenta, Peter A.

AU - Carson, Linda F.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Objectives. To assess the antitumor activity of Temozolomide, a novel alkylating agent, in patients with persistent or recurrent ovarian or primary peritoneal carcinoma who have failed other second-line chemotherapy agents. To identify the nature and degree of toxicity of Temozolomide in this group of patients. Methods. Temozolomide was administered orally at an initial dose of 150 mg/m2 daily for 5 days, every 4 weeks. If the initial course was tolerated without dose-limiting toxicity, then the dose was increased to 200 mg/m2. Patients were evaluated for response and toxicity. Results. Fifteen patients were enrolled and evaluated. The median number of prior treatment regimens was 3. Hematologic toxicity was encountered in 26% of patients and was manageable. There were no complete or partial responses. One patient had stable disease with significant improvement in her performance status while on treatment. Conclusion. This dose and schedule of Temozolomide had insignificant activity in this heavily pretreated group of patients with persistent or recurrent ovarian or primary peritoneal carcinoma.

AB - Objectives. To assess the antitumor activity of Temozolomide, a novel alkylating agent, in patients with persistent or recurrent ovarian or primary peritoneal carcinoma who have failed other second-line chemotherapy agents. To identify the nature and degree of toxicity of Temozolomide in this group of patients. Methods. Temozolomide was administered orally at an initial dose of 150 mg/m2 daily for 5 days, every 4 weeks. If the initial course was tolerated without dose-limiting toxicity, then the dose was increased to 200 mg/m2. Patients were evaluated for response and toxicity. Results. Fifteen patients were enrolled and evaluated. The median number of prior treatment regimens was 3. Hematologic toxicity was encountered in 26% of patients and was manageable. There were no complete or partial responses. One patient had stable disease with significant improvement in her performance status while on treatment. Conclusion. This dose and schedule of Temozolomide had insignificant activity in this heavily pretreated group of patients with persistent or recurrent ovarian or primary peritoneal carcinoma.

KW - Peritoneal carcinoma

KW - Temozolomide

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=2942657534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942657534&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.03.020

DO - 10.1016/j.ygyno.2004.03.020

M3 - Article

C2 - 15196862

AN - SCOPUS:2942657534

VL - 93

SP - 667

EP - 670

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -